Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Equity Ratio (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Equity Ratio for 6 consecutive years, with 0.79 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Equity Ratio fell 5.79% year-over-year to 0.79, compared with a TTM value of 0.79 through Jun 2025, down 5.79%, and an annual FY2023 reading of 0.87, down 3.15% over the prior year.
  • Equity Ratio was 0.79 for Q2 2025 at Barinthus Biotherapeutics, down from 0.81 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.96 in Q2 2021 and bottomed at 0.32 in Q1 2021.
  • Average Equity Ratio over 5 years is 0.81, with a median of 0.88 recorded in 2023.
  • Peak annual rise in Equity Ratio hit 378.81% in 2022, while the deepest fall reached 7.08% in 2022.
  • Year by year, Equity Ratio stood at 0.9 in 2021, then grew by 0.04% to 0.9 in 2022, then dropped by 3.15% to 0.87 in 2023, then fell by 3.06% to 0.85 in 2024, then dropped by 6.4% to 0.79 in 2025.
  • Business Quant data shows Equity Ratio for BRNS at 0.79 in Q2 2025, 0.81 in Q1 2025, and 0.85 in Q3 2024.